This document is an excerpt from the EUR-Lex website
Document 62022TB0278
Case T-278/22 R: Order of the President of the General Court of 4 August 2022 — Biogen Netherlands v Commission (Interim relief — Medicinal products for human use — Regulation (EC) No 726/2004 — Marketing authorisation for Dimethyl fumarate Neuraxpharm — dimethyl fumarate — Application for suspension of operation of a measure — No urgency)
Case T-278/22 R: Order of the President of the General Court of 4 August 2022 — Biogen Netherlands v Commission (Interim relief — Medicinal products for human use — Regulation (EC) No 726/2004 — Marketing authorisation for Dimethyl fumarate Neuraxpharm — dimethyl fumarate — Application for suspension of operation of a measure — No urgency)
Case T-278/22 R: Order of the President of the General Court of 4 August 2022 — Biogen Netherlands v Commission (Interim relief — Medicinal products for human use — Regulation (EC) No 726/2004 — Marketing authorisation for Dimethyl fumarate Neuraxpharm — dimethyl fumarate — Application for suspension of operation of a measure — No urgency)
OJ C 398, 17.10.2022, p. 27–27
(BG, ES, CS, DA, DE, ET, EL, EN, FR, GA, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
|
17.10.2022 |
EN |
Official Journal of the European Union |
C 398/27 |
Order of the President of the General Court of 4 August 2022 — Biogen Netherlands v Commission
(Case T-278/22 R)
(Interim relief - Medicinal products for human use - Regulation (EC) No 726/2004 - Marketing authorisation for Dimethyl fumarate Neuraxpharm - dimethyl fumarate - Application for suspension of operation of a measure - No urgency)
(2022/C 398/32)
Language of the case: English
Parties
Applicant: Biogen Netherlands BV (Badhoevedorp, Netherlands) (represented by: C. Schoonderbeek, lawyer)
Defendant: European Commission (represented by: L. Haasbeek and A. Sipos, acting as Agents)
Re:
By its application based on Articles 278 and 279 TFEU, the applicant seeks suspension of the operation of Commission Implementing Decision C(2022) 3254 final of 13 May 2022 granting marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council for ‘Dimethyl fumarate Neuraxpharm — dimethyl fumarate’ as a medicinal product for human use.
Operative part of the order
|
1. |
The application for interim measures is dismissed. |
|
2. |
The costs are reserved. |